Europe Advisory Panel Rejects Sarepta’s Duchenne Drug Once Again

Sarepta Therapeutics won one of the most controversial drug approvals in recent memory, when the FDA in September 2016 approved the Duchenne muscular dystrophy drug eteplirsen (Exondys 51) off a slim set of data. The Cambridge, MA, company isn’t having the same luck in Europe.